Coloplast A/S banner

Coloplast A/S
CSE:COLO B

Watchlist Manager
Coloplast A/S Logo
Coloplast A/S
CSE:COLO B
Watchlist
Price: 401.8 DKK 2.01% Market Closed
Market Cap: kr90.4B

EV/GP

5.9
Current
49%
Cheaper
vs 3-y average of 11.5

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
5.9
=
Enterprise Value
kr128.3B
/
Gross Profit
kr18.9B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
5.9
=
Enterprise Value
kr128.3B
/
Gross Profit
kr18.9B

Valuation Scenarios

Coloplast A/S is trading below its 3-year average

If EV/GP returns to its 3-Year Average (11.5), the stock would be worth kr786.68 (96% upside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
-43%
Maximum Upside
+110%
Average Upside
40%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 5.9 kr401.8
0%
3-Year Average 11.5 kr786.68
+96%
5-Year Average 12.3 kr841.93
+110%
Industry Average 5.8 kr397.51
-1%
Country Average 3.3 kr227.37
-43%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close
P/E Multiple
Earnings Growth PEG
DK
Coloplast A/S
CSE:COLO B
Average P/E: 28.4
22.8
21%
1.1
JP
Hoya Corp
TSE:7741
37.6
15%
2.5
US
M
Medline Inc
NASDAQ:MDLN
Not Available
30%
N/A
CH
Alcon AG
SIX:ALC
36.3
32%
1.1
US
Align Technology Inc
NASDAQ:ALGN
31.1
34%
0.9
CA
Bausch + Lomb Corp
NYSE:BLCO
Negative Multiple: -16 N/A N/A
UK
ConvaTec Group PLC
LSE:CTEC
31.1
41%
0.8
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
23
9%
2.6
CN
Intco Medical Technology Co Ltd
SZSE:300677
21.9
12%
1.8
KR
H
HLB Inc
KOSDAQ:028300
Negative Multiple: -36.5 N/A N/A
US
Lantheus Holdings Inc
NASDAQ:LNTH
23.6
30%
0.8

Market Distribution

In line with most companies in Denmark
Percentile
68th
Based on 336 companies
68th percentile
5.9
Low
0.1 — 1.8
Typical Range
1.8 — 6.4
High
6.4 —
Distribution Statistics
Denmark
Min 0.1
30th Percentile 1.8
Median 3.3
70th Percentile 6.4
Max 57.4

Coloplast A/S
Glance View

Coloplast A/S, headquartered in Humlebæk, Denmark, has a storied history that dates back to 1954 when a nurse, Elise Sørensen, identified a crucial need in the healthcare sector. Her sister had undergone ostomy surgery, and the lack of appropriate post-operative care products inspired Sørensen to design the world’s first adhesive ostomy bag. This innovation laid the groundwork for Coloplast's trajectory in the healthcare industry. Today, the company has expanded its focus to include ostomy care, continence care, wound and skin care, and interventional urology. With a commitment to improving patients' quality of life, Coloplast has become a leader in designing and manufacturing products that not only highlight practicality but also embody comfort and discretion. Coloplast generates revenue through a business model that emphasizes product innovation and direct engagement with healthcare providers and patients. The company invests significantly in research and development to improve and widen its product offerings continuously. It operates globally, distributing its products directly and via partnerships with hospitals, clinics, and healthcare professionals. By maintaining an attentive approach to user experience and incorporating customer feedback into its development processes, Coloplast ensures its portfolio aligns with the actual needs of its users. This user-centered strategy not only enhances customer loyalty but also fortifies the company’s market position, driving its financial success.

COLO B Intrinsic Value
623.95 DKK
Undervaluation 36%
Intrinsic Value
Price kr401.8
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett